NBSE NASDAQ
NeuBase Therapeutics, Inc.
1W: +0.0%
1M: -14.5%
3M: -59.0%
1Y: -90.5%
3Y: -99.6%
5Y: -99.3%
$0.38
Last traded 2024-05-24 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$1M
-119.4% ▼
Operating Income
-$33M
-25.4% ▼
Net Income
-$34M
-33.4% ▼
EPS (Diluted)
$-21.08
-12.1% ▼
EBITDA
-$33M
-27.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $14M | $128K | $280K | $576K | $1M |
| Gross Profit | -$14M | -$128K | -$280K | -$576K | -$1M |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $4M | $17M | $7M | $14M | $21M |
| SG&A Expenses | $4M | $9M | $10M | $12M | $12M |
| Operating Expenses | $9M | $26M | $17M | $27M | $33M |
| Operating Income | -$14M | -$26M | -$17M | -$27M | -$33M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $129K | $8K | $32K | $24K |
| Income Before Tax | -$13M | -$27M | -$17M | -$25M | -$34M |
| Tax Expense | $9M | $129K | -$123K | $258K | $458K |
| Net Income | -$13M | -$27M | -$17M | -$26M | -$34M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-93.57 | $-65.49 | $-17.60 | $-18.80 | $-21.08 |
| EBITDA | -$3M | -$27M | -$17M | -$26M | -$33M |
| Shares Outstanding | 141462 | 413585 | 981014 | 1M | 2M |